June 9, 2023 07:23 AM EDT
R&D

Disc Med­i­cine claims PhII win for re­pur­posed ex-Roche drug in rare blood dis­or­der

Amber Tong

When Disc Med­i­cine closed a $62.5 mil­lion raise led by Bain Cap­i­tal ear­li­er this year, the biotech’s CEO John Quisel point­ed to the stream of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times